Curis is an oncology-focused company seeking to develop and commercialize next generation targeted drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also developing its pipeline of proprietary targeted cancer drug candidates, including CUDC-427, a small molecule antagonist of IAP proteins; CUDC-907, a dual PI3K and HDAC inhibitor; and CUDC-101, an EGFR/Her2 and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.
Curis is developing several proprietary clinical-stage small molecules in testing for various cancers, including antagonist of IAP proteins CUDC-427, dual PI3K and HDAC inhibitor CUDC-907 and EGFR/Her2 and HDAC inhibitor CUDC-101.
Curis’ collaborator Genentech (Roche) is commercializing Hedgehog pathway inhibitor Erivedge® (vismodegib) in the U.S. for advanced basal cell carcinoma. Roche continues to seek approvals for Erivedge in several different territories in this lead indication and is also testing Erivedge in less severe forms of BCC. Several additional clinical studies are ongoing under collaborations between Genentech and the National Cancer Institute and independent study investigators.
Curis licensee Debiopharm is also conducting clinical studies on HSP90 inhibitor Debio 0932 in patients with advanced lung cancer and expects to initiate additional testing in patients with renal cell carcinoma during the second half of 2013.
Director, Business Development:
Job Code: BD800
Curis is seeking a Director of Business Development responsible for leading strategic business development initiatives. The position reports to the Chief Financial and Business Officer. The individual will be expected to work closely with the other members of the executive management and the broader Curis team involved in transaction evaluation, diligence and execution. In this role, the candidate will take ownership of key business initiatives and develop both in- and out-licensing objectives and programs consistent with Curis’ corporate strategy; source deal opportunities; lead multifunctional teams to handle due diligence; engage in complex contract negotiations; work productively with legal counsel, and deliver presentations for research and product-based collaborations.
The individual will source and evaluate potential business opportunities by performing discounted cash flow/NPV analysis, evaluating market comparables, deal requirements, technical and financial risks, strategic value and attributes of prospective collaborators. The individual must be comfortable with advancing multiple projects concurrently, assessing strategic options and making clear recommendations to senior management and the Board of Directors. We expect that in this role the candidate will continually update job knowledge by participating in educational opportunities and conferences, reading professional publications and maintaining professional networks. In addition, the individual will support research and development activities by negotiating and closing significant contracts related to R&D operations.
This individual will also participate in corporate intelligence and corporate communications related to Curis’ research and development programs.
Desired Skills & Experience
Personal Skills & Competencies
Curis, Inc. (the “Company” or “Curis”) is an oncology-focused company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Curis conducts research and development programs both internally and through strategic collaborations. Erivedge® is the first and only approved medicine for the treatment of advanced basal cell carcinoma, and is being commercialized by Roche and Genentech under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop clinical-stage targeted cancer programs CUDC-427 and a small molecule IAP inhibitor and CUDC-907, a dual PI3K and HDAC inhibitor. Curis licensee Debiopharm is progressing the clinical development of HSP90 inhibitor, Debio 0932.
Qualified candidates should submit their CVs, with job code, via email to email@example.com, via fax to 617-503-6501, or mail to:
No phone calls please.
Curis, Inc. is an Equal Opportunity Employer.